![\"\"](\"https:\/\/www.360prwire.com\/wp-content\/uploads\/2021\/10\/curative-biotech-300x47.png\")
<\/p>\n<\/p>\n
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License\u00a0 Beyond Treatment of Symptomatic Rabies\u00a0<\/span><\/i><\/p>\n Boca Raton, FL, October 7, 2021 \u2014 Curative Biotechnology, Inc. (OTC: CUBT) (\u201cCurative Biotech\u201d\u00a0 or the \u201cCompany\u201d) announced today that the Company has reached an agreement with Mid Atlantic BioTherapeutics (MABT) to broaden its previously announced license of IMT504,\u00a0 a novel patented immunotherapy and adjuvant, to include the development of a next-generation COVID-19 vaccine. The Company will initially develop the vaccine to address the kidney failure patient population. This new license, utilizing IMT504 as an adjuvant on top of a\u00a0 proprietary protein vaccine, adds a second infectious disease program to the Curative Biotech <\/span>product development portfolio which also includes a reformulation of Metformin licensed from the National Eye Institute at National Institutes of Health (NIH) to treat degenerative eye diseases, and a novel monoclonal antibody\/drug combination to treat brain cancer licensed from the National Cancer Institute at NIH.\u00a0<\/span><\/p>\n \u201cIt is becoming increasingly clear that the initial COVID-19 vaccines developed are not working for everyone. There are highly vulnerable people, such as those patients with kidney failure who require kidney transplantation or dialysis, who are being left behind. We need targeted vaccines for this immunocompromised patient group,\u201d said Curative Biotech Chairman and\u00a0<\/span>President Paul Michaels.\u00a0<\/span><\/p>\n Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next-generation COVID-19 vaccine targeted to meet the needs of this vulnerable population. A consequence of kidney failure, in general, is the loss of a robust immunologic response to infections, including\u00a0 COVID-19. This means that kidney failure patients may get a more severe version of COVID-19\u00a0 that could lead to a greater chance of hospitalization or even death.\u00a0<\/span><\/p>\n Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: \u201cIt is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines. Recent data from\u00a0 France reveals that, <\/span>even after 4 vaccine shots, many kidney transplant recipients have poor responses<\/span>. In addition, kidney failure patients on dialysis do not initially respond as well to\u00a0 current vaccines and <\/span>rapidly lose measurable antibodies when compared to the general <\/span>\u00a0<\/span>population<\/span>.\u201d\u00a0<\/span><\/p>\n As previously announced, Curative Biotech has acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies. Curative Biotech and MABT are already working together to develop IMT504 to treat patients whose disease has advanced to a stage where the virus has migrated to the brain, causing lethal rabies encephalitis. There are\u00a0<\/span>currently no treatment options for these patients. IMT504 has already been granted orphan drug designation in the US for the treatment of rabies, which may provide significant benefits including tax credits, market exclusivity, and the waiver of certain FDA fees. Rabies is one of only a limited number of diseases that qualify for the FDA Tropical Disease Priority Review Voucher\u00a0 (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria. Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.\u00a0<\/span><\/p>\n Chairman Michaels concluded, \u201cWe are excited to begin work on this additional program and\u00a0 expect to announce additional important management resources at Curative Biotech to\u00a0 supplement the clinical development team.\u201d\u00a0<\/span><\/p>\n Future Curative Biotechnology Press Releases and Industry Updates\u00a0<\/b><\/p>\n Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to <\/span>ir@curativebiotech.com<\/span>.\u00a0<\/span><\/p>\n About Mid-Atlantic BioTherapeutics, Inc. <\/b>https:\/\/mabt.us\/<\/span>\u00a0<\/span><\/p>\n Mid-Atlantic BioTherapeutics was founded in 2011 with the mission of eradicating infectious diseases. MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of novel anti-infective approaches, such as the patented IMT504\u00a0 immunotherapy platform, that harnesses the body\u2019s own immune response to fight off infections. The company is actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for bacterial and viral diseases, emerging infectious diseases, and biodefense.\u00a0<\/span><\/p>\n About Curative Biotechnology, Inc. <\/b>http:\/\/curativebiotech.com<\/span>\u00a0<\/span><\/p>\n Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a\u00a0 product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity,\u00a0 Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a\u00a0 therapeutic option.\u00a0<\/span><\/p>\n Forward-Looking Statements\u00a0<\/b><\/p>\n This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934.\u00a0 CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently\u00a0<\/span>subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited to our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets Group from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition,\u00a0 results of operation, and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.\u00a0<\/span><\/p>\n Media Contact:\u00a0<\/strong><\/p>\n Steve Chizzik\u00a0<\/span><\/p>\n Investor Relations\u00a0<\/span><\/p>\n Curative Biotech (CUBT)\u00a0<\/span><\/p>\n 201-454-5845\u00a0<\/span><\/p>\n ir@curativebiotech.com<\/p>\n \u00a0<\/p>\n PR Contact \u2013<\/strong><\/p>\n Ron von Dyck (SVP Global Sales)<\/p>\n Contact: D. Jonas (AVP \u2013 360PRLaw 360PRWire, LLC<\/p>\n![\"\u2122\"](\"https:\/\/s.w.org\/images\/core\/emoji\/13.1.0\/72x72\/2122.png\")
) \u2013 Dom@360prwire.com<\/p>\n